Comments
Transcript
Curriculum Vitae Education: Name: Claire Keating
Curriculum Vitae Name: Claire Keating Address: 622 West 168th Street PH8 -859 New York, NY 10032 Education: Cornell University, College of Agriculture and Life Sciences, Ithaca, NY B.S. with Honors Biological Sciences, May 1997 1997 Tufts University School of Medicine, Boston, MA MD, May 2003 2003 Postdoctural Training New York Presbyterian Hospital – Weill Cornell Medical Center Intern and Resident Internal Medicine 2003-2006 International Elective - Cape Town, South Africa Respiratory Clinic, Groote Schuur Hospital/University of Cape Town Feb 2006 New York Presbyterian Hospital – Columbia Medical Center Fellow Pulmonary and Critical Care Medicine 2006-2009 Board Certification: New York State License Diplomate, American Board of Internal Medicine Sub-specialty Pulmonary Disease Sub-specialty Critical Care Medicine 2005 2006 2008 2009 Professional Organizations: American Thoracic Society American College of Chest Physicians 2006 2007 Academic Appointments: Assistant Professor of Clinical Medicine Columbia University, College of Physician and Surgeons 2009-present Associate Director, Gunnar Esiason Adult Cystic Fibrosis and Lung Center Columbia University Medical Center 2009-present Committees and Collaboratives: Cystic Fibrosis Foundation Therapeutics, Inc. Data Safety and Monitoring Board Member 2012-present Cystic Fibrosis Foundation Therapeutic Drug Network Publications and Presentations Committee Member 2012-present NYC-Clinical Data Research Network Stakeholder Advisory Board Member 2014-present Hospital Appointments: Assistant Professor of Clinical Medicine New York Presbyterian Hospital-Columbia Medical Center 2006-present Past Awards: Honors in Biological Sciences Major, Cornell University Golden Key National Honor Society, Cornell University Presidential Award for Citizenship and Public Service, Tufts University Daniel M. Libby Program Director’s Award for Clinical Excellence; Cornell Medical Center Adult Quality Improvement 3 Learning and Leadership Collaborative Award; Cystic Fibrosis Foundation, Team Champion OneCF Learning and Leadership Collaborative 2 Award Cystic Fibrosis Foundation, Team Leader 1997 1997 2001 2006 2013 2015 Lectures, teaching and responsibilities: Cystic Fibrosis and the Adult Patient Medicine Grand Rounds Methodist Hospital, Brooklyn, NY March 2012 Bronchiectasis diagnosis and management: Annual pulmonary fellowship didactic seminar Columbia University Medical Center 2010-present Cystic Fibrosis diagnosis and management: Annual allergy fellowship didactic seminar Columbia University Medical Center 2012-present Pulmonary Consultation Attending Physician Columbia University Medical Center 2009-present Pulmonary Function Test interpretation preceptor Columbia University Medical Center 2009-present Research Activity: A Phase 3, Randomized, Double Blind, Placebo Controlled Parallel-Group 7/2015 Study to Evaluate the Efficacy and Safety of VX661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Heterozygous for F508del-CFTR Mutation and With a Second CFTR Mutation that is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy Vertex Pharmaceuticals Inc. Role: Principal Investigator A Multicenter, Randomized Double Blind, Placebo Controlled 04/2015-present Study to Evaluate the Efficacy and Safety of Pulmaquin in the Management Chronic Lung Infections with Pseudomonas in Subjects with Non-Cystic Fibrosis Bronchiectasis Aradigm Corporation Role: Co-Investigator A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Cystic Fibrosis PTC Therapeutics Role: Co-Investigator 03/2015-present A Phase 2, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX 661 in Combination with Ivacaftor for 12 Weeks in Subjects with Cystic Fibrosis, Homozygous for the F508del CFTR Mutation Vertex Pharmaceuticals Inc. Role: Principal Investigator 04/2014-present A Phase 2, Multicenter, Double Blind, Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation—Cohort 4 Vertex Pharmaceuticals Inc. Role: Principal Investigator 06/2013-present Cystic Fibrosis Foundation C079-TDC09Y Columbia University Therapeutics Development Network Role: Co-PI 01/01/10-present Publications: Wiedmann M, Bruce JL, Keating C, Johnson AE, McDonough PL, Batt CA. Ribotypes and virulence gene polymorphisms suggest three distinct Listeria monocytogenes lineages with differences in pathogenic potential. Infection & Immunity 1997 Jul;65(7):2707-16. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001 Oct 1;98(7):2059-64. Keating C, Wang S, Brenner K, Wang T, Powell C. Circulating Progenitor Cells in Non-Small Cell Lung Cancer Patients. Poster presentation, American Thoracic Society Annual Meetings, Toronto, Canada 2008. Am. J. Respir. Critical Care Med, 2008. Keating C, Liu X, DiMango E. Characteristics of Adult Diagnosis of CF from the CF Foundation Registry. Poster Presentation, North American Cystic Fibrosis Conference, Orlando, FL 2008. Pediatric Pulmonology, 2008. Keating C, Liu X, DiMango E. Predictors of Lung Function in Cystic Fibrosis at Diagnosis. Poster Discussion Session, American Thoracic Society Annual Meetings, San Diego 2009. Am. J. Respir. Critical Care Med, 2009. Keating, C. L., D'Souza, B. M., Mason, D. M., Shu, C. A.; DiMango, E. A., Austin, J. H.M. Adult-Diagnosis of CF – Does it Differ at CT Scan from the Pediatric Population? North American Cystic Fibrosis Conference, Minneapolis, MN 2009. Pediatric Pulmonology, 2009. Keating CL, Liu X, Dimango EA,; Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. Chest. 2010 May;137(5):1157-63. Dimango E, Walker P, Keating C, Berdella M, Robinson N, Langfelder-Schwind E, et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulm Med. 2014 Feb 15;14:21. Keating C, Poor A, Liu X, Dimango E. Delayed diagnosis of cystic fibrosis have slower FEV1 decline but higher risk of death or transplant over time. Workshop Presentation, North American Cystic Fibrosis Conference, Atlanta, GA 2014. Pediatric Pulmonology, 2014.